Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (GB:0XOD)
LSE:0XOD
Earnings Data
Report Date
Mar 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.8Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong progress in the ZUSDURI launch and JELMYTO revenue growth, offset by challenges in operational execution and increased expenses. The permanent J-code for ZUSDURI is anticipated to drive future growth, but current operational delays and increased net loss are notable concerns.Company Guidance
ZUSDURI Launch Progress
Preliminary demand revenue for October more than doubled the previous three months, indicating increased usage and adoption. Physician enthusiasm and high intent to prescribe remain strong, with market access team securing broad coverage across major payers.
JELMYTO Revenue Growth
Net product revenue for JELMYTO reached $25.7 million, representing a 13% increase in underlying demand revenue compared to the same period in 2024.
Clinical Advancements
The 3-month complete response rate from the UTOPIA study aligns with previous trials, supporting plans for an NDA submission for UGN-103 in the second half of 2026, with potential approval in 2027.
Strong Market Access for ZUSDURI
ZUSDURI is accessible to 95% of covered lives, with approximately 296 million eligible patients, showing excellent market access progress.
Permanent J-code for ZUSDURI
A permanent J-code will go into effect on January 1, 2026, expected to accelerate adoption, particularly in community settings.
GB:0XOD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0XOD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $19.23 | $22.50 | +17.00% |
Aug 07, 2025 | $19.45 | $19.08 | -1.89% |
May 12, 2025 | $10.33 | $10.95 | +6.03% |
Mar 10, 2025 | $9.95 | $9.70 | -2.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Urogen Pharma (GB:0XOD) report earnings?
Urogen Pharma (GB:0XOD) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
What is Urogen Pharma (GB:0XOD) earnings time?
Urogen Pharma (GB:0XOD) earnings time is at Mar 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Urogen Pharma stock?
The P/E ratio of Urogen Pharma is N/A.
What is GB:0XOD EPS forecast?
GB:0XOD EPS forecast for the fiscal quarter 2025 (Q4) is -0.48.